Clinical & Experimental Cardiology

Clinical & Experimental Cardiology
Open Access

ISSN: 2155-9880

Short Communication - (2025)Volume 16, Issue 7

View PDF Download PDF

Red Rice DE 40 and its Potential in Alleviating Hyperlipidemia

Durairajan Sudha1, Sundaresan Uma2, Ganesan Ariharasivakumar3*, Selvaraj Varalakshmi1, Muthiah Chellapandian4 and Patrick A. Kalona5
 
*Correspondence: Ganesan Ariharasivakumar, Department of Pharmacology, KMCH College of Pharmacy, Coimbatore, Tamil Nadu, India, Email:

Author info »

Abstract

Hyperlipidemia, a condition marked by elevated plasma lipid levels, is a major risk factor for cardiovascular diseases, obesity, and metabolic syndromes. Conventional lipid-lowering therapies, such as statins, are effective but often carry side effects, necessitating safer, natural alternatives. Red Rice (RR) DE 40, a bioactive-rich extract, has demonstrated antihyperlipidemic effects in preclinical studies. This mini-review summarizes current evidence on RR DE 40's efficacy in reducing body weight, modulating lipid profiles, improving liver function, and correcting hematological disturbances in High-Fat Diet (HFD)-induced hyperlipidemic rats. RR DE 40 showed comparable results to rosuvastatin and exhibited no toxicity at high doses. These findings support further exploration of RR DE 40 as a potential natural alternative for managing hyperlipidemia and associated disorders.

Keywords

Hyperlipidemia; Red rice DE 40; Lipid metabolism; Obesity; Natural therapy; Cholesterol; Triglycerides; Cardiovascular disease

Description

Hyperlipidemia, particularly when induced by poor diet and sedentary lifestyle, plays a central role in the development of Cardiovascular Diseases (CVDs), including atherosclerosis, myocardial infarction, and stroke [1,2]. Characterized by elevated levels of Total Cholesterol (TC), Triglycerides (TG), Low-Density Lipoproteins (LDL), and reduced High-Density Lipoproteins (HDL), hyperlipidemia poses significant health risks globally [3]. While statins and fibrates are commonly used lipid-lowering agents, their side effects—ranging from muscle myopathy to liver dysfunction—warrant the search for safer alternatives [4,5]. Dietary fiber intake and consumption of antioxidant-rich foods can improve obesity-related lipid disorders. Red Rice (Oryza sativa) is a whole grain rich in anthocyanins and polyphenols. Recent studies on RR DE 40, a concentrated red rice extract, suggest it possesses strong lipid-lowering, hepatoprotective, and antiinflammatory properties [6-8]. This mini-review explores current evidence regarding RR DE 40’s effect on lipid metabolism in experimental hyperlipidemia.

Hyperlipidemia results from genetic and environmental factors, particularly high-fat diets, leading to metabolic imbalance and systemic inflammation [9]. The accumulation of LDL and VLDL in the vasculature promotes oxidative stress and the progression of atherosclerosis [10]. Conventional lipid-lowering medications like statins, while effective, are often associated with side effects including elevated liver enzymes, gastrointestinal issues, and insulin resistance [11]. These concerns have spurred interest in natural products that modulate lipid metabolism without inducing systemic toxicity [12]. Natural substances such as polyphenols, flavonoids, and plant sterols have shown potential in managing hyperlipidemia by inhibiting cholesterol absorption and synthesis, and promoting lipid catabolism [13].

In a controlled study, rats fed a high-fat diet developed hyperlipidemia characterized by increased TC, TG, LDL, and VLDL levels, along with body weight gain and fatty liver morphology [14]. RR DE 40, administered at 250 and 500 mg/ kg from day 60 to 90, significantly reduced these parameters, comparable to rosuvastatin [15]. Notably, HDL levels were also improved in RR DE 40-treated groups. RR DE 40 treatment ameliorated HFD-induced liver damage by decreasing SGPT and SGOT activity, supported by histopathological analysis showing restored hepatocyte structure [16,17]. Moreover, the extract normalized hematological disturbances, including WBC and monocyte levels, which are often elevated in metabolic inflammation [18]. An acute toxicity study showed no mortality or adverse effects at doses up to 2000 mg/kg, confirming the extract's safety profile [19]. This supports its candidacy for further testing and potential therapeutic use.

Conclusion

Red Rice DE 40 has demonstrated significant lipid-lowering, hepatoprotective, and anti-inflammatory effects in preclinical models of hyperlipidemia. Its ability to reduce LDL, VLDL, and TG levels, while increasing HDL and maintaining liver function, positions it as a promising natural therapeutic agent. With a strong safety profile and comparable efficacy to rosuvastatin, RR DE 40 warrants further investigation through clinical studies. As a nutraceutical or adjunct to conventional therapy, it may contribute meaningfully to the management of hyperlipidemia and the prevention of cardiovascular diseases.

References

Author Info

Durairajan Sudha1, Sundaresan Uma2, Ganesan Ariharasivakumar3*, Selvaraj Varalakshmi1, Muthiah Chellapandian4 and Patrick A. Kalona5
 
1Department of Biochemistry, Islamiah Women’s Arts & Science college, Affiliated to Thiruvalluvar University, Tamil Nadu, India
2Department of Food Process Engineering, School of Bioengineering, SRM University, Kattankulathur, Tamil Nadu, India
3Department of Pharmacology, KMCH College of Pharmacy, Coimbatore, Tamil Nadu, India
4PG and Research Department of Botany, V.O.Chidambaram College, Thoothukudi, Tamil Nadu, India
5Centre for Research and Development, P.T. Phytochemindo Reska, Bogor, Indonesia
 

Citation: Sudha D, Uma S, Ariharasivakumar G, Varalakshmi S, Chellappandian M, Kalona PA (2025). Red Rice DE 40 and its Potential in Alleviating Hyperlipidemia-Mini Review. J Clin Exp Cardiolog. 16:962.

Received: 16-Apr-2025, Manuscript No. JCEC-25-37273; Editor assigned: 21-Apr-2025, Pre QC No. JCEC-25-37273 (PQ); Reviewed: 05-May-2025, QC No. JCEC-25-37273; Revised: 12-May-2025, Manuscript No. JCEC-25-37273 (R); Published: 19-May-2025 , DOI: 10.35248/2155-9880.25.16.962

Copyright: © 2025 Sudha D, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Top